Wen-Chih Chiang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6627533/publications.pdf

Version: 2024-02-01

69 papers	4,031 citations	147801 31 h-index	114465 63 g-index
69 all docs	69 docs citations	69 times ranked	4593 citing authors

#	Article	IF	Citations
1	The journey from erythropoietin to 2019 Nobel Prize: Focus on hypoxia-inducible factors in the kidney. Journal of the Formosan Medical Association, 2021, 120, 60-67.	1.7	10
2	Spectrum of cancer patients receiving renal biopsy. Journal of the Formosan Medical Association, 2021, 121, 152-152.	1.7	0
3	Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-Î² signaling in kidney fibroblasts. Journal of Clinical Investigation, 2021, 131, .	8.2	52
4	Angiopoietin-2 is associated with metabolic syndrome in chronic kidney disease. Journal of the Formosan Medical Association, 2021, 120, 2113-2119.	1.7	5
5	Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis. Kidney International, 2021, 99, 1354-1368.	5.2	19
6	Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients. Frontiers in Immunology, 2021, 12, 638309.	4.8	20
7	Transforming growth factor-Î²1 decreases erythropoietin production through repressing hypoxia-inducible factor 2Î± in erythropoietin-producing cells. Journal of Biomedical Science, 2021, 28, 73.	7.0	5
8	Inflammatory macrophages switch to CCL17â€expressing phenotype and promote peritoneal fibrosis. Journal of Pathology, 2020, 250, 55-66.	4.5	37
9	Methylation in pericytes after acute injury promotes chronic kidney disease. Journal of Clinical Investigation, 2020, 130, 4845-4857.	8.2	32
10	Associations between preoperative continuation of reninâ€“angiotensin system inhibitor and cardiac surgery-associated acute kidney injury: a propensity score-matching analysis. Journal of Nephrology, 2019, 32, 957-966.	2.0	5
11	SP300ANGIOPOIETIN-1 ATTENUATES INFLAMMATION AND FIBROSIS THROUGH ACTIVATED ENDOTHELIUM. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
12	FP211THE IMPACT OF ACUTE PODOCYTE INJURY ON GLOMERULAR FUNCTION AND CELLS CHANGE IN REPAIR PROCESS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
13	A KDM6Aâ€“KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction. EMBO Molecular Medicine, 2019, 11, .	6.9	52
14	Emergency department utilization and resuscitation rate among patients receiving maintenance hemodialysis. Journal of the Formosan Medical Association, 2019, 118, 1652-1660.	1.7	8
15	Angiopoietin 1 influences ischemic reperfusion renal injury via modulating endothelium survival and regeneration. Molecular Medicine, 2019, 25, 5.	4.4	17
16	Erythropoietin modulates macrophages but not post-ischemic acute kidney injury in mice. Journal of the Formosan Medical Association, 2019, 118, 494-503.	1.7	5
17	The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy. Journal of the Formosan Medical Association, 2019, 118, 898-906.	1.7	11
18	Heart rate variability as a predictor of rapid renal function deterioration in chronic kidney disease patients. Nephrology, 2019, 24, 806-813.	1.6	18

#	Article	IF	Citations
19	Anti-CD20 therapy and pauci-immune crescentic glomerulonephritis. Journal of the Formosan Medical Association, 2017, 116, 215-216.	1.7	2
20	Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. Scientific Reports, 2017, 7, 44013.	3.3	6
21	Early initiation of immunosuppressive treatment in membranous nephropathy patients. Journal of the Formosan Medical Association, 2017, 116, 266-275.	1.7	3
22	Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update. Journal of Biomedical Science, 2017, 24, 84.	7.0	22
23	Pentoxifylline: Evidence strong enough forÂrenoprotection?. Journal of the Formosan Medical Association, 2016, 115, 591-592.	1.7	13
24	DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys. Journal of Clinical Investigation, 2016, 126, 721-731.	8.2	68
25	Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-ÎºB and Smad2/3 Signaling. Molecular Medicine, 2015, 21, 276-284.	4.4	272
26	Reply to comment on â€œRenoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney diseaseâ€. Journal of the Formosan Medical Association, 2015, 114, 95-96.	1.7	1
27	Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment. Journal of the Formosan Medical Association, 2015, 114, 102-111.	1.7	101
28	Multidisciplinary Care Program for Advanced Chronic Kidney Disease: Reduces Renal Replacement and Medical Costs. American Journal of Medicine, 2015, 128, 68-76.	1.5	88
29	Ileum and colon perforation following peritoneal dialysis-related peritonitis and high-dose calcium polystyrene sulfonate. Journal of the Formosan Medical Association, 2015, 114, 1008-1010.	1.7	17
30	Lineage Tracing Reveals Distinctive Fates for Mesothelial Cells and Submesothelial Fibroblasts during Peritoneal Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 2847-2858.	6.1	117
31	Long-Term Outcomes after Dialysis-Requiring Acute Kidney Injury. BioMed Research International, 2014, 2014, 1-11.	1.9	34
32	A case of anaphylactic shock induced by <scp>FX</scp>60 polysulfone hemodialyzer but not <scp>F6â€HPS</scp> polysulfone hemodialyzer. Hemodialysis International, 2014, 18, 841-845.	0.9	9
33	Long-Term Risk of Coronary Events after AKI. Journal of the American Society of Nephrology: JASN, 2014, 25, 595-605.	6.1	262
34	Blockade of cysteine-rich protein 61 attenuates renal inflammation and fibrosis after ischemic kidney injury. American Journal of Physiology - Renal Physiology, 2014, 307, F581-F592.	2.7	34
35	Too much salt inflames our body: Fact or artifact?. Journal of the Formosan Medical Association, 2014, 113, 671-672.	1.7	2
36	Angiopoietin-2â€“Induced Arterial Stiffness in CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 1198-1209.	6.1	42

#	Article	IF	Citations
37	Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. Journal of the Formosan Medical Association, 2014, 113, 219-226.	1.7	283
38	MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction. Journal of the American Society of Nephrology: JASN, 2014, 25, 1698-1709.	6.1	158
39	Comments on â€œProgression of stages 3bâ€“5 chronic kidney diseaseâ€”Preliminary results of Taiwan national pre-ESRD disease management program in Southern Taiwanâ€. Journal of the Formosan Medical Association, 2014, 113, 770-771.	1.7	2
40	Transforming Growth Factor Î²-1 Stimulates Profibrotic Epithelial Signaling to Activate Pericyte-Myofibroblast Transition in Obstructive Kidney Fibrosis. American Journal of Pathology, 2013, 182, 118-131.	3.8	206
41	Cysteine-Rich Protein 61 Plays a Proinflammatory Role in Obstructive Kidney Fibrosis. PLoS ONE, 2013, 8, e56481.	2.5	27
42	Angiopoietins Modulate Endothelial Adaptation, Glomerular and Podocyte Hypertrophy after Uninephrectomy. PLoS ONE, 2013, 8, e82592.	2.5	3
43	Clinical Outcomes and Predictors for ESRD and Mortality in Primary GN. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1401-1408.	4.5	61
44	Advanced age affects the outcome-predictive power of RIFLE classification in geriatric patients with acute kidney injury. Kidney International, 2012, 82, 920-927.	5.2	59
45	Impact of timing of renal replacement therapy initiation on outcome of septic acute kidney injury. Critical Care, 2011, 15, R134.	5.8	87
46	Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. Kidney International, 2011, 80, 1222-1230.	5.2	163
47	Targeting Endothelium-Pericyte Cross Talk by Inhibiting VEGF Receptor Signaling Attenuates Kidney Microvascular Rarefaction and Fibrosis. American Journal of Pathology, 2011, 178, 911-923.	3.8	224
48	Combining body mass index and serum potassium to urine potassium clearance ratio is an alternative method to predict primary aldosteronism. Clinica Chimica Acta, 2011, 412, 1637-1642.	1.1	4
49	Primary aldosteronism. Journal of Hypertension, 2011, 29, 1778-1786.	0.5	81
50	Platelet-derived growth factor receptor signaling activates pericyteâ€“myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney International, 2011, 80, 1170-1181.	5.2	273
51	Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients. Journal of the Formosan Medical Association, 2010, 109, 663-672.	1.7	11
52	Establishment of Protein Delivery Systems Targeting Podocytes. PLoS ONE, 2010, 5, e11837.	2.5	9
53	Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment. Nephrology, 2008, 13, 198-203.	1.6	4
54	Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial. American Journal of Kidney Diseases, 2008, 52, 464-474.	1.9	325

#	Article	IF	Citations
55	Bradykinin enhances reactive oxygen species generation, mitochondrial injury, and cell death induced by ATP depletionâ€"A role of the phospholipase CCa2+ pathway. Free Radical Biology and Medicine, 2007, 43, 702-710.	2.9	11
56	Poor Renal Outcome of Antineutrophil Cytoplasmic Antibody Negative Pauci-immune Glomerulonephritis in Taiwanese. Journal of the Formosan Medical Association, 2006, 105, 804-812.	1.7	33
57	Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney International, 2006, 69, 1410-1415.	5.2	66
58	Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radical Biology and Medicine, 2006, 41, 1304-1314.	2.9	43
59	Thoracic kidney and contralateral ureteral duplicationâ€"a case report and review of the literature. Nephrology Dialysis Transplantation, 2006, 21, 799-801.	0.7	13
60	YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1â€"Independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. European Journal of Pharmacology, 2005, 517, 1-10.	3.5	17
61	Pentoxifylline Attenuates Tubulointerstitial Fibrosis by Blocking Smad3/4-Activated Transcription and Profibrogenic Effects of Connective Tissue Growth Factor. Journal of the American Society of Nephrology: JASN, 2005, 16, 2702-2713.	6.1	142
62	The Renoprotective Potential of Pentoxifylline in Chronic Kidney Disease. Journal of the Chinese Medical Association, 2005, 68, 99-105.	1.4	19
63	Pentoxifylline suppresses renal tumour necrosis factor-Â and ameliorates experimental crescentic glomerulonephritis in rats. Nephrology Dialysis Transplantation, 2004, 19, 1106-1115.	0.7	51
64	Dual Regulation of Tumor Necrosis Factor-Î±-Induced CCL2/Monocyte Chemoattractant Protein-1 Expression in Vascular Smooth Muscle Cells by Nuclear Factor-ÎºB and Activator Protein-1: Modulation by Type III Phosphodiesterase Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 978-986.	2.5	62
65	Pentoxifylline: A potential therapy for chronic kidney disease. Nephrology, 2004, 9, 198-204.	1.6	32
66	Antineutrophil cytoplasmic antibody-associated glomerulonephritis in Taiwanese. Nephrology, 2004, 9, 297-303.	1.6	4
67	Tumor necrosis factor-Î± stimulates fractalkine production by mesangial cells and regulates monocyte transmigration: Down-regulation by cAMP. Kidney International, 2003, 63, 474-486.	5.2	29
68	Pentoxifylline Inhibits Platelet-Derived Growth Factor-Stimulated Cyclin D1 Expression in Mesangial Cells by Blocking Akt Membrane Translocation. Molecular Pharmacology, 2003, 64, 811-822.	2.3	34
69	Pentoxifylline Attenuated the Renal Disease Progression in Rats with Remnant Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 2916-2929.	6.1	106